CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $638,106 | -15.9% | 23,187 | +3.7% | 0.00% | -20.0% |
| Q2 2023 | $758,777 | -4.7% | 22,363 | +1.1% | 0.01% | 0.0% |
| Q1 2023 | $795,806 | -17.6% | 22,118 | +2.0% | 0.01% | -28.6% |
| Q4 2022 | $966,144 | +57.9% | 21,677 | -0.4% | 0.01% | +75.0% |
| Q3 2022 | $612,000 | +5.9% | 21,756 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $578,000 | -25.7% | 21,449 | -6.1% | 0.00% | 0.0% |
| Q1 2022 | $778,000 | -17.6% | 22,831 | -6.6% | 0.00% | -20.0% |
| Q4 2021 | $944,000 | -30.5% | 24,438 | -2.9% | 0.01% | -28.6% |
| Q3 2021 | $1,359,000 | +84.9% | 25,169 | +14.6% | 0.01% | +250.0% |
| Q2 2021 | $735,000 | – | 21,970 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |